Shih, C., Chen, V.J., Gossett, L.S., Gates, S.B., MacKellar, W.C., Habeck, L.L., Shackelford, K.A., Mendelsohn, L.G., Soose, D.J., Patel, V.F., Andis, S.L., Bewley, J.R., Rayl, E.A., Moroson, B.A., Beardsley, G.P., Kohler, W., Ratnam, M. and Schultz, R.M. (1997) LY231514, a Pyrrolo[2,3-d]Pyrimidine-Based Antifolate That Inhibits Multiple Folate-Requiring Enzymes. Cancer Research, 57, 1116-1123.

has been cited by the following article:

• TITLE: Good Response to Pemetrexed after Treatment Failure with Another Thymidylate Synthase Inhibitor in Lung Adenocarcinoma: A Case Report

  AUTHORS: Fumihiko Hirai, Eiko Inamasu, Gouji Toyokawa, Tsukihisa Yoshida, Kaname Nosaki, Tomoyoshi Takenaka, Masafumi Yamaguchi, Mitsuhiro Takenoyama, Takashi Seto, Yukito Ichinose

  KEYWORDS: Pemetrexed, S-1, Thymidylate Synthase

  JOURNAL NAME: Journal of Cancer Therapy, Vol.5 No.8, July 10, 2014

  ABSTRACT: Pemetrexed is an antimetabolic agent and is well-known as a potent inhibitor of thymidylate synthase (TS). It also inhibits dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyl transferase (GARFT). We reported an intriguing case in which a non-small cell lung cancer patient who was refractory to pretreatment with S-1, a strong TS inhibitor, showed good response to pemetrexed treatment.